Stanton J M
Eating Disorders Service, Auckland Hospital, New Zealand.
Schizophr Bull. 1995;21(3):463-72. doi: 10.1093/schbul/21.3.463.
In this article we review the empirical literature on weight gain associated with neuroleptic drug use. Weight gain, which appears to be associated with an increase in appetite, is variable but likely to be larger initially and then plateau. Clozapine and low-potency phenothiazines are associated with the largest gains and molindone with weight loss, but the mechanism is not known. Amantadine and fenfluramine may reverse weight gain to some degree. Dietary fat seems to play an important role in obesity, and research is needed to increase the data base and elucidate possible mechanisms. Studies are also needed to evaluate preventive strategies and to determine which drugs are least likely to produce weight gain as well as which drugs could be added to a neuroleptic regimen to control weight.
在本文中,我们回顾了关于使用抗精神病药物导致体重增加的实证文献。体重增加似乎与食欲增加有关,其变化不定,但最初可能增加较多,随后趋于平稳。氯氮平和低效价吩噻嗪类药物导致的体重增加最多,而吗茚酮则与体重减轻有关,但其机制尚不清楚。金刚烷胺和芬氟拉明在一定程度上可能会逆转体重增加。膳食脂肪似乎在肥胖中起重要作用,需要开展研究以增加相关数据库并阐明可能的机制。还需要开展研究以评估预防策略,并确定哪些药物最不可能导致体重增加,以及哪些药物可添加到抗精神病药物治疗方案中以控制体重。